In the face of conflicting evidence over the risks and benefits of routine prostate cancer screenings, a large, longitudinal analysis found Veterans Health Administration (VA) medical centers with lower prostate screening rates had higher rates of metastatic prostate cancer cases in subsequent years than centers with higher screening rates.
|
A new study, presented at the annual ASTRO meeting, finds that sexual side effects of cancer treatment are discussed far less frequently with female patients than with male patients, even when the treatment directly affects sex organs.
|
|
|
|
|
|
Rogel Cancer Center faculty and trainees will lead 30 presentations, posters and moderated sessions at the American Society of Radiation Oncology annual meeting. This year’s meeting will be held in-person, virtually and on-demand.
|
Researchers at the University of Michigan Rogel Cancer Center have developed a computational platform that can predict new and specific metabolic targets in ovarian cancer, suggesting opportunities to develop personalized therapies for patients that are informed by the genetic makeup of their tumors.
|
An international team of researchers led by the University of Michigan Rogel Cancer Center received a collaborative grant from the National Cancer Institute with a goal of bringing new insights into leiomyosarcoma, a rare form of cancer that seemingly originates in smooth muscle. The grant, worth $12.3 million, is through the NCI’s SPORE, or Specialized Program of Research Excellence, which funds collaborative, interdisciplinary translational cancer research.
|
Drugs like enzalutamide that inhibit male hormones from activating the androgen receptor have been used to treat advanced prostate cancer for more than a decade. While successful in most cases, these drugs can eventually stop working, but there is a limited understanding about how this change occurs.
|
|
|
MENU